ArticleNature2025
A coronavirus assembly inhibitor that targets the viral membrane protein.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins.ChemMedChem · 2026Review
- Substrate-Selective Inhibition of the SARS-CoV-2 Papain-Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Rab10 coordinates SADS-CoV non-lytic egress through the ERGIC-TGN-lysosome trafficking pathway.PLoS pathogens · 2026Article
- Direct lipid interactions control SARS-CoV-2 M protein conformational dynamics and virus assembly.Nature communications · 2026Article
- Coronavirus M Protein Hijacks Toll-Interacting Protein (TOLLIP) to Suppress NF-κB Signaling and Promote Immune Evasion.MedComm · 2026Article
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Rational Design of Broad-Spectrum Anti-Enteroviral Molecular Glues Targeting Enteroviral RNAi Suppressors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- In Vitro Analysis and Dynamic Modeling of SARS-CoV-2 Infection Inhibition by Sigma-1 Receptor Antagonist PB28.Bulletin of mathematical biology · 2026Article
- Scalable and sustainable manufacturing of functional DNA nanoassemblies via self-folding circular single-stranded DNA.Nature communications · 2026Article
- Coronavirus M protein disperses the trans-Golgi network and inhibits anterograde protein trafficking in the secretory pathway.PLoS pathogens · 2026Article
- Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research.Microbial biotechnology · 2026Review
- Beyond assembly: functions of the coronavirus M protein.Virology journal · 2026Review
- Potency ofThe Kobe journal of medical sciences · 2026Article
- Clustering of SARS-CoV-2 membrane proteins in lipid bilayer membranes.PLoS computational biology · 2026Article
- Targeting the host factor HGS-viral membrane protein interaction in coronavirus infection.The Journal of clinical investigation · 2026Article
- SARS-CoV-2 membrane protein biogenesis.bioRxiv : the preprint server for biology · 2026Article
- The structure and function of membrane protein in coronavirus infection and its applications in the development of vaccines and therapeutic drugs.Frontiers in microbiology · 2026Review
- Inhibitory Effects of Enoxolone on Porcine Epidemic Diarrhea Virus In Vitro and In Vivo.Transboundary and emerging diseases · 2026Article
- From HIV to SARS-CoV-2 associated neurological disorder ("HAND" to "SAND"): Viral infection as a "time-bomb" for the aging brain.Neuroscience applied · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors.
Manon Laporte *Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0001-5708-1321
Dirk Jochmans *Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0002-9265-6028
Dorothée BardiotCISTIM Leuven vzw, Leuven, Belgium.
Lowiese DesmaretsCNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Université de Lille, Lille, France.ORCID 0000-0001-5077-3333
Oliver J Debski-AntoniakVirology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-8239-2738
Giulia MizzonDepartment of Infectious Diseases, Molecular Virology, Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0001-9392-9748
Rana AbdelnabiVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0001-9771-7312
Pieter LeyssenVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0002-7537-1688
Winston ChiuVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0001-5236-623X
Zhikuan ZhangGraduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
Norimichi NomuraDepartment of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6330-2239
Sandro BolandCISTIM Leuven vzw, Leuven, Belgium.
Umeharu OhtoGraduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.ORCID 0000-0002-4422-4044
Yannick StahlDepartment of Infectious Diseases, Molecular Virology, Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0003-0861-4907
Jurgen WuytsCISTIM Leuven vzw, Leuven, Belgium.
Steven De JongheStructural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0002-3872-6558
Annelies StevaertStructural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0003-3316-2826
Martijn J van HemertMolecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Brenda W BontesMolecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1520-2265
Patrick WanningenMolecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
G J Mirjam GroenewoldMolecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-6280-7297
Aneta ZegarVirogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.ORCID 0000-0003-0005-2890
Katarzyna OwczarekVirogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.ORCID 0000-0002-2166-4688
Sanjata JoshiInstitute of Molecular Medicine and German Center for Infection Research (DZIF), University of Lübeck, Lübeck, Germany.
Mohamed KoukniCISTIM Leuven vzw, Leuven, Belgium.
Philippe ArzelCISTIM Leuven vzw, Leuven, Belgium.
Hugo KlaassenCISTIM Leuven vzw, Leuven, Belgium.
Jean-Christophe VanherckCISTIM Leuven vzw, Leuven, Belgium.
Ilse VandecaetsbeekCISTIM Leuven vzw, Leuven, Belgium.
Niels CremersVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0003-4506-2857
Kim DonckersVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Thibault FranckenVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Tina Van BuytenVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Jasper RymenantsVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.ORCID 0000-0003-3838-310X
Joost SchepersVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Krzysztof PyrcVirogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.ORCID 0000-0002-3867-7688
Rolf HilgenfeldInstitute of Molecular Medicine and German Center for Infection Research (DZIF), University of Lübeck, Lübeck, Germany.
Jean DubuissonCNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Université de Lille, Lille, France.ORCID 0000-0003-1626-7693
Berend-Jan BoschVirology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-3864-232X
Frank Van KuppeveldVirology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-5800-749X
Cecilia EydouxArchitecture et Fonction des Macromolécules Biologiques (AFMB), Aix-Marseille Univ., CNRS, Faculté des Sciences Campus Luminy, Marseille, France.ORCID 0000-0003-4181-592X
Etienne DecrolyArchitecture et Fonction des Macromolécules Biologiques (AFMB), Aix-Marseille Univ., CNRS, Faculté des Sciences Campus Luminy, Marseille, France.ORCID 0000-0002-6046-024X
Bruno CanardArchitecture et Fonction des Macromolécules Biologiques (AFMB), Aix-Marseille Univ., CNRS, Faculté des Sciences Campus Luminy, Marseille, France.
Lieve NaesensStructural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Birgit WeynandDepartment of Imaging and Pathology, Division of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.ORCID 0000-0003-4246-6303
Eric J SnijderMolecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-3297-2309
Sandrine BelouzardCNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Université de Lille, Lille, France.ORCID 0000-0002-9972-4054
Toshiyuki ShimizuGraduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.ORCID 0000-0002-0547-8922
Ralf BartenschlagerDepartment of Infectious Diseases, Molecular Virology, Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0001-5601-9307
Daniel L HurdissVirology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-3834-5808
Arnaud MarchandCISTIM Leuven vzw, Leuven, Belgium.
Patrick ChaltinCISTIM Leuven vzw, Leuven, Belgium.
Johan NeytsVirology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium. johan.neyts@kuleuven.be.ORCID 0000-0002-0033-7514
Funding
Development of an Oral Pan-Coronavirus Drug CocktailR01AI177512 · NIAID · UNIVERSITY OF WASHINGTON · PI STEPHEN J. POLYAK, Joshua Tisdell Schiffer · 2023 to 2026
$2.7MGates Foundation INV-006366NIAID NIH HHS R01 AI177512
Abstract
The coronavirus membrane protein (M) is the main organizer of coronavirus assembly
Indexed as
Antiviral AgentsCoronavirus M ProteinsCOVID-19 Drug TreatmentSARS-CoV-2Virus AssemblyAdministration, OralAnimalsChlorocebus aethiopsCOVID-19CricetinaeCryoelectron MicroscopyFemaleHumansLungMaleMesocricetusAntiviral AgentsCoronavirus M Proteinsmembrane protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.